Literature DB >> 15502911

[Evidence based medicine indications for radiation therapy in testicular germ cell tumours].

R Souchon1, J Classen, H Schmidberger.   

Abstract

The intensity of adjuvant radiotherapy for stage I seminoma could be reduced substantially in recent years, achieving cure with low side effects and a low probability of late complications. Today a dose of 20 Gy is applied to the para-aortic lymphatics. Valuable treatment alternatives to radiotherapy have emerged: surveillance strategy allows 80% of patients to avoid further treatment. However, the remaining 20% will be exposed to potentially more intensive salvage therapy. Adjuvant carboplatinum chemotherapy offers similar disease-free survival to adjuvant radiotherapy. Long-term experience with late toxicity is not available. In seminoma CS IIA/B curative irradiation remains the standard treatment. Brain metastases of testicular germ cell tumors are treated with a combination of chemotherapy and cranial irradiation. In intratubular germ cell neoplasia (TIN), radiotherapy with 20 Gy will safely eliminate all TIN loci, but will destroy potential residual fertility.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15502911     DOI: 10.1007/s00120-004-0706-3

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  16 in total

Review 1.  [Interdisciplinary consensus in diagnosis and therapy of testicular tumors. Results of an update conference founded on evidence-based medicine (EBM)].

Authors:  S Krege; H J Schmoll; R Souchon
Journal:  Urologe A       Date:  2001-03       Impact factor: 0.639

2.  Radiotherapy in stage I seminoma of the testis.

Authors:  Alan Horwich
Journal:  J Clin Oncol       Date:  2004-01-15       Impact factor: 44.544

3.  Radiotherapy for stage II testicular seminoma.

Authors:  G K Zagars; A Pollack
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-11-01       Impact factor: 7.038

4.  Combination carboplatin and radiotherapy in the management of stage II testicular seminoma: comparison with radiotherapy treatment alone.

Authors:  H Patterson; A R Norman; S S Mitra; J Nicholls; C Fisher; D P Dearnaley; A Horwich; M D Mason; R A Huddart
Journal:  Radiother Oncol       Date:  2001-04       Impact factor: 6.280

5.  International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group.

Authors: 
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

6.  Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group.

Authors:  S D Fosså; A Horwich; J M Russell; J T Roberts; M H Cullen; N J Hodson; W G Jones; H Yosef; G M Duchesne; J R Owen; E J Grosch; A D Chetiyawardana; N S Reed; B Widmer; S P Stenning
Journal:  J Clin Oncol       Date:  1999-04       Impact factor: 44.544

Review 7.  Treatment of early stage testicular seminoma.

Authors:  J Classen; R Souchon; T Hehr; M Bamberg
Journal:  J Cancer Res Clin Oncol       Date:  2001-08       Impact factor: 4.553

8.  Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma.

Authors:  J Aparicio; X García del Muro; P Maroto; L Paz-Ares; E Alba; A Sáenz; J Terrasa; A Barnadas; D Almenar; J A Arranz; M Sánchez; A Fernández; J Sastre; J Carles; J Dorca; J Gumà; A L Yuste; J R Germà
Journal:  Ann Oncol       Date:  2003-06       Impact factor: 32.976

9.  Para-aortic irradiation for stage I testicular seminoma: results of a prospective study in 675 patients. A trial of the German testicular cancer study group (GTCSG).

Authors:  J Classen; H Schmidberger; C Meisner; C Winkler; J Dunst; R Souchon; L Weissbach; V Budach; W Alberti; M Bamberg
Journal:  Br J Cancer       Date:  2004-06-14       Impact factor: 7.640

10.  Radiotherapy with 16 Gy may fail to eradicate testicular intraepithelial neoplasia: preliminary communication of a dose-reduction trial of the German Testicular Cancer Study Group.

Authors:  J Classen; K Dieckmann; M Bamberg; R Souchon; S Kliesch; M Kuehn; V Loy
Journal:  Br J Cancer       Date:  2003-03-24       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.